{"request_id":"7fe4688f5d427a94b63e7ad5603e46d8","results":{"ticker":"AMGN","name":"Amgen Inc","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0000318154","composite_figi":"BBG000BBS2Y0","share_class_figi":"BBG001S5NNL6","market_cap":139994337091.32,"phone_number":"(805)447-1000","address":{"address1":"ONE AMGEN CENTER DRIVE","city":"THOUSAND OAKS","state":"CA","postal_code":"91320"},"description":"Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).","sic_code":"2836","sic_description":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","ticker_root":"AMGN","homepage_url":"https://www.amgen.com","total_employees":25200,"list_date":"1983-06-17","share_class_shares_outstanding":534900000,"weighted_shares_outstanding":534901181,"round_lot":100},"status":"OK"}
